{
  "pmcid": "12365376",
  "sha256": "f296f1dd622b4112d8e07a3299f8b1eaa9dbf395a6bf6f48917dbcd71d0c6633",
  "timestamp_utc": "2025-11-09T23:34:25.356096+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.375909926470587,
    "reading_ease": 25.985450367647076,
    "word_count": 256
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Engineered Extracellular Vesicles in Osteoarthritis Treatment"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised into two groups"
      },
      "Participants": {
        "score": 2,
        "evidence": "adults with clinically diagnosed knee OA. Conducted as a randomised controlled trial at a tertiary care hospital"
      },
      "Intervention": {
        "score": 2,
        "evidence": "the intervention group received engineered EVs, while the control group received standard care"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the potential of engineered extracellular vesicles (EVs) as a novel therapeutic approach for OA"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome, joint function improvement, was assessed over a 12-month period"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved using a computer-generated sequence, with allocation concealment ensured through sealed envelopes"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group assignments"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised, with 100 allocated to each group, during the recruitment period from January 2020 to June 2021"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "An intention-to-treat analysis was performed on 98 participants in the intervention group and 97 in the control group"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group exhibited a significant improvement in joint function (mean difference = 5.2, 95% CI 3.1 to 7.3; p = 0.01)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were minimal, with 3% of the intervention group and 1% of the control group experiencing mild gastrointestinal side-effects"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Institutes of Health"
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}